ReviewBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2022
Renal amyloidosis: a new time for a complete diagnosis.
Review in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Clinical manifestations, diagnosis and treatment of hereditary fibrinogen Aα-chain renal amyloidosis: one case report and systematic review.International urology and nephrology · 2025Pooled it
- Acute kidney injury with interstitial hemorrhage in renal heavy chain amyloidosis: a clinicopathologic case report.CEN case reports · 2026Article
- Pathogenesis and kidney prognosis of renal amyloidosis.Cellular and molecular life sciences : CMLS · 2026Review
- Fibrillary Glomerulonephritis and Apolipoprotein A-IV Amyloidosis: A Rare Dual Pathology Diagnosed by Mass Spectrometry and DNAJB9 Immunohistochemistry.Kidney medicine · 2026Article
- Hypercoagulability in Light Chain Amyloidosis and the Importance of Predictive Value of TEG and TGT for Thrombosis Recurrence in Inflammatory States.Diagnostics (Basel, Switzerland) · 2026Article
- Concurrence of renal amyloidosis and membranous nephropathy: a case series and literature review.BMC nephrology · 2026Review
- Adalimumab for AA Amyloidosis Secondary to Severe Hidradenitis Suppurativa.Case reports in nephrology · 2026Article
- Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis.Haematologica · 2025Article
- Article
- Article
- Histopathology of Diabetic Nephropathy: Beyond Glomerular Basement Membrane Thickening.Cureus · 2025Review
- Comparative Insights on Inpatient Outcomes in Diastolic Heart Failure with and Without Amyloidosis: A Nationwide Propensity-Matched Analysis.Journal of cardiovascular development and disease · 2025Article
- The Proteome Content of Blood Clots Observed Under Different Conditions: Successful Role in Predicting Clot Amyloid(ogenicity).Molecules (Basel, Switzerland) · 2025Review
- Therapeutic potential ofFrontiers in pharmacology · 2025Article
- Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology.Current issues in molecular biology · 2024Review
- AA Amyloidosis: A Contemporary View.Current rheumatology reports · 2024Review
- Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis.Clinical cardiology · 2024Article
- Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report.World journal of clinical cases · 2023Article
- Familial Mediterranean Fever in Spain: Time Trend and Spatial Distribution of the Hospitalizations.International journal of environmental research and public health · 2023Article
- Analysis of survival among biopsy-determined categories of kidney disease in dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidoses are a group of disorders in which soluble proteins aggregate and deposit extracellularly in tissues as insoluble fibrils, causing organ dysfunction. Clinical management depends on the subtype of the protein deposited and the affected organs. Systemic amyloidosis may stem from anomalous proteins, such as immunoglobulin light chains or serum amyloid proteins in chronic inflammation or may arise from hereditary disorders. Hereditary amyloidosis consists of a group of rare conditions that do not respond to chemotherapy, hence the identification of the amyloid subtype is essential for diagnosis, prognosis, and treatment. The kidney is the organ most frequently involved in systemic amyloidosis. Renal amyloidosis is characterized by acellular pathologic Congo red-positive deposition of amyloid fibrils in glomeruli, vessels, and/or interstitium. This disease manifests with heavy proteinuria, nephrotic syndrome, and progression to end-stage kidney failure. In some situations, it is not possible to identify the amyloid subtype using immunodetection methods, so the diagnosis remains indeterminate. In cases where hereditary amyloidosis is suspected or cannot be excluded, genetic testing should be considered. Of note, laser microdissection/mass spectrometry is currently the gold standard for accurate diagnosis of amyloidosis, especially in inconclusive cases. This article reviews the clinical manifestations and the current diagnostic landscape of renal amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.